UNIVERSITY of CALIFORNIA SAN DIEGO Responses of Germline

Total Page:16

File Type:pdf, Size:1020Kb

UNIVERSITY of CALIFORNIA SAN DIEGO Responses of Germline UNIVERSITY OF CALIFORNIA SAN DIEGO Responses of Germline Targeting Immunogens to Influenza A Thesis submitted in partial satisfaction of the requirements for the degree Master of Science in Biology by Justin Romualdo Abadejos Committee in charge: Professor Stephen Hedrick, Chair Professor Li-Fan Lu, Co-Chair Professor Elina Zuniga 2018 Copyright Justin Romualdo Abadejos, 2018 All rights reserved. The Thesis of Justin Romualdo Abadejos is approved and it is acceptable in quality and form for publication on microfilm and electronically: Co-Chair Chair University of California San Diego 2018 iii DEDICATION I would like to thank everyone at the old Kirak lab: Oktay Kirak, Manching Ku, Nathaniel Phillips, Niklas Münchmeier, Shih-En Chang, Julio Hernandez, Jesus Zaragoza, Amy Nham, and Brett Freeman for taking me in and introducing me to the world of science. I would like to also thank Dr. Stephen Hedrick, Dr. Li-Fan Lu, and Dr. Zuniga for allowing me to continue my research at TSRI and for acting as my committee. I would also like to thank everyone at the Nemazee lab: David Nemazee, Amanda Gavin, Patrick Skog, Tanya Blane, Deli Huang, Sabrina Volpi, Miyo Ota, Terri Thinnes, and Wenjuan Li for taking me in to a wonderful family and helping me along the way. A special thank you to David Nemazee, Takayuki Ota, Shanshan Lang for being wonderful mentors and for guiding me throughout my time in science. I want to take the time to thank Nicole Aguirre, for continuously pushing me to be my best and supporting me in everything I do. A huge thank you and odes of appreciation to my parents, Efren and Tessie Abadejos for putting up with me and being my foundation, words can’t explain how grateful I am for you two. I’d like to dedicate this thesis to my grandfather and my late grandmother, Felix and Isadora Romualdo. iv EPIGRAPH “Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it's the only thing that ever has.” -Margaret Mead “If you want to go fast, go alone. If you want to go far, go together.” -African Proverb v TABLE OF CONTENTS Signature Page ..……………………………………………………………………. iii Dedication ...……………………………………………………………………….. iv Epigraph …………………………………………………………………………… v Table of Contents ...………………………………………………………………... vi List of Abbreviations ………………………………………………………………. vii List of Figures ……………………………………………………………………… ix List of Tables ………………………………………………………………………. xi Acknowledgements ………………………………………………………………... xii Vita…………………………………………………………………………………. xiii Abstract of the Thesis ...…………………………..……………………………….. xiv Chapter 1: Introduction…………………………………………………………….. 1 1.1: Figures………………………………………………………………… 9 Chapter 2: Testing the ability of anti-idiotype K1-18 and engineered HA 587H1-X to induce a broadly neutralizing HA stem response in a 9114 gH mouse model…….. 16 2.1: Generation of a 9114 gH mouse model……………………………….. 16 2.2: Testing of anti-idiotypic antibody K1-18 as a germline targeting immunogen…………………………………………………………………. 17 2.3: Testing of engineered HA 587H1-X as a germline targeting immunogen…………………………………………………………………. 20 2.4: Discussion……………………………………………………………… 24 2.5: Methods………………………………………………………………... 30 2.6: Figures and Tables…………………………………………………...… 42 References…………………………………………………………………………... 57 vi LIST OF ABBREVIATIONS BLI biolayer inferometry bnAb broadly neutralizing antibody BSA bovine serum albumin CDR complementarity determining region CDRH complementarity determining region heavy chain ELISA Enzyme linked immunosorbent assay FAB fragment antigen binding FACS fluorescence-activated cell sorting Fc fragment crystallizable FR framework region gH germline heavy chain GL germline HA hemagglutinin IgG immunoglobulin G Kd dissociation constant M molar MHC major histocompatibility complex NA neuraminidase Ni-NTA nickel-nitrilotriacetic acid PBMC peripheral blood mononuclear cells PBS phosphate buffered saline vii PDB Protein Data Bank PEG polyethylene glycol SSRL Stanford Synchrotron Radiation Lightsource UCA unmutated common ancestor viii LIST OF FIGURES Figure 1.1. The influenza life cycle and potential immune responses……………… 9 Figure 1.2. Structures and subtypes of hemagglutinin……………………………… 10 Figure 1.3. Isolation, identification, and theoretical development of broadly neutralizing antibodies………………………………………………………………. 11 Figure 1.4. Crystal structures revealing HA stem binding contacts of VH1-69 bnAb CR6261……………………………………………………………………….. 12 Figure 1.5. VH1-69 bnAbs utilizing key CDRH2 residues to bind to HA stem…..... 13 Figure 1.6. Binding ability of various influenza bnAbs to the different HA subtypes 14 Figure 1.7. DNA Vaxibody dimer structure………………………………………... 15 Figure 2.1. Design of 9114 gH knock-in mice……………………………………... 42 Figure 2.2. Characterization of the B6 9114 gH Mouse Model……………………. 43 Figure 2.3. Structure and paratope of K1-18……………………….………….…… 44 Figure 2.4. K1-18 activates B6 9114 gH B cells…………………………………… 45 Figure 2.5. K1-18 Immunizations show 587H1-X IFY enhancing mutation-specific response via Octet…………………………………………………………………… 46 Figure 2.6. K1-18 Immunizations show 9114-specific, 587H1-X IFY enhancing mutation-specific response via competitive ELISA……………………………..…. 47 Figure 2.7. Vaxibody DNA immunizations with K1-18 scFv as the antigenic unit show responses to K1-18 and 587H1 via endpoint titre ELISA………………………….. 48 Figure 2.8. Structures outlining mutations in Cali09/H1 that improve binding to germline VH1-69 bnAb CR6261……………………………………………………………… 50 Figure 2.9. In vitro binding and activation of 587X-H1 to B6 9114 gH B cells…… 51 Figure 2.10. 587H1-X Immunizations show IFY motif enhancing mutation-specific response via octet and ELISA assays………………………………………………. 52 Figure 2.11. Immunizations of B6 9114 gH mice with 587H1-X generate mutations in 9114 heavy chain…………………………………………………………………. 54 ix Figure 2.12. Future directions in testing germline targeting immunogens for development of influenza broadly neutralizing antibodies………………………………………… 56 x LIST OF TABLES Table 2.1. Mutations in Cali09/H1 that improve binding to germline VH1-69 bnAb CR6261……………………………………………………………………………… 49 xi ACKNOWLEDGEMENTS I’d like to thank Shanshan Lang (TSRI) for developing our germline targeting immunogens, providing and creating protein for analysis, for structures of K1-18, 587H1- X, CR6261, CR9114, and 27F3; Takayuki Ota (TSRI) for generating the 9114 gH mouse model, for help characterizing the mouse model, for proving mutation analysis data and in general for all his help and mentorship on all aspects of this project; Stephen M. Hedrick, Li-Fan Lu, and Elina Zuniga for allowing me to continue my research at TSRI and for gratefully serving on my committee; Patrick Skög for his help with optimizing immunizations; Tanya Blane for her help with mouse techniques and immunizations; Gunnveig Grødeland for mentorship and providing the vaxibody construct; TSRI’s FACS ++ core for help with flow cytometry and providing resources for FACS analysis and Ca flux; TSRI’s department of animal resources for outstanding services. Lastly, I’d like to thank Dr. David Nemazee for his oversight of the entire project and his mentorship and guidance throughout these past two years. xii VITA 2016 Bachelor of Science, Human Biology, University of California San Diego 2016-2017 Teaching Assistant, Department of Biological Sciences University of California San Diego 2018 Master of Science, Biology, University of California San Diego PUBLICATIONS Ku, M., S. E. Chang, J. Hernandez, J. R. Abadejos, M. Sabouri-Ghomi, N. J. Muenchmeier, A. Schwarz, A. M. Valencia and O. Kirak (2016). "Nuclear transfer nTreg model reveals fate-determining TCR-beta and novel peripheral nTreg precursors." Proc Natl Acad Sci U S A 113(16): E2316-2325. FIELDS OF STUDY Major Field: Human Biology Studies in Immunology Professors Oktay Kirak and David Nemazee xiii ABSTRACT OF THE THESIS Response of Germline Targeting Immunogens to Influenza by Justin Romualdo Abadejos Master of Science in Biology University of California San Diego, 2018 Professor Stephen Hedrick, Chair Professor Li-Fan Lu, Co-Chair Influenza virus is a constant threat to international public health. The current, seasonal vaccine generates a response to epitopes of influenza virus that have a high rate xiv of mutation leading to antigenic drift and antigenic shift leaving current memory responses useless and potentially resulting in a pandemic. The need for a universal influenza vaccine is evident. High affinity, broadly neutralizing antibodies (bnAbs) against a conserved epitope of the influenza virion, such as the stem of hemagglutinin, show potential to protect against a wide breadth, if not all influenza viruses. Identifying germline precursors of these bnAbs and generating immunogens that drive the maturation of a heterosubtypic response could provide a universal answer to influenza. In this thesis, I show the development and characterization of a mouse model consisting of B cells containing the germline heavy chain of the influenza bnAb CR9114. Furthermore, I outline the responses of two germline targeting immunogens to influenza: an anti-idiotypic antibody known as K1-18 and an engineered variant of an H1- hemagglutinin protein known as 587H1-X. Both K1-18 and 587H1-X are shown via calcium flux and activation markers to simulate B cells of our 9114 gH mouse model. Immunization studies with both immunogens show their ability to generate an IgG response that cross binds to wild type hemagglutinin. 587H1-X in particular shows mutation capabilities that drive these gl9114 antibodies towards
Recommended publications
  • Vaccines Innovative
    2013 MeDiciNes iN DeVelopmeNT REPORT Vaccines A Report on the Prevention and Treatment of Disease Through Vaccines PRESENTED BY AMERICA’s biopharmACEUTICAL RESEARCH COMPANIES Nearly 300 Vaccines Are in Development; Research Focuses on Prevention and Treatment For many years, vaccines have been used • A monoclonal antibody vaccine that to successfully prevent devastating infec- targets both pandemic and seasonal tious diseases such as smallpox, measles influenza. and polio. According to data from the • A genetically-modified vaccine designed Vaccines in Development* U.S. Centers for Disease Control and for the treatment of pancreatic cancer. Prevention (CDC), 10 infectious diseases Application Submitted have been at least 90 percent eradicated • An irradiated vaccine for protection in the United States thanks to vaccines. Phase III against malaria. This has protected millions of children Phase II and families from needless illness. The development and regulatory path that these vaccine candidates face is Phase I These public health triumphs illustrate the complex. As with the development of all major contributions that vaccines have drugs, the majority of vaccines must pre- 137 made in saving countless lives around vail through years of clinical testing before the world. In the past several years, they can be approved for use by the gen- through our growing understanding of eral public. However, advances in other the molecular underpinnings of disease scientific fields, such as genomics and and technological advances, many new manufacturing technologies, are becom- vaccines have been developed, including ing increasingly useful in the development one against human papillomavirus (HPV) of new vaccines. The continued efforts 99 infections that can lead to cervical cancer, of researchers within biopharmaceutical a vaccine to guard against the anthrax companies and across the ecosystem, virus before exposure, and a vaccine to who are pursuing new techniques and prevent pneumococcal infections in high- strategies in vaccine development, cre- risk populations.
    [Show full text]
  • New Class of Monoclonal Antibodies Against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets
    New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets Robert H. E. Friesen1*, Wouter Koudstaal1, Martin H. Koldijk1, Gerrit Jan Weverling1, Just P. J. Brakenhoff1, Peter J. Lenting1, Koert J. Stittelaar2, Albert D. M. E. Osterhaus2,3, Ronald Kompier1, Jaap Goudsmit1 1 Crucell Holland BV, Leiden, The Netherlands, 2 ViroClinics BV, Rotterdam, The Netherlands, 3 Department of Virology, ErasmusMC, Rotterdam, The Netherlands Abstract Background: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic. A recently discovered class of human monoclonal antibodies with the ability to neutralize a broad spectrum of influenza viruses (including H1, H2, H5, H6 and H9 subtypes) has the potential to prevent and treat influenza in humans. Here we report the latest efficacy data for a representative antibody of this novel class. Methodology/Principal Findings: We evaluated the prophylactic and therapeutic efficacy of the human monoclonal antibody CR6261 against lethal challenge with the highly pathogenic avian H5N1 virus in ferrets, the optimal model of human influenza infection. Survival rates, clinically relevant disease signs such as changes in body weight and temperature, virus replication in lungs and upper respiratory tract, as well as macro- and microscopic pathology were investigated. Prophylactic administration of 30 and 10 mg/kg CR6261 prior to viral challenge completely prevented mortality, weight loss and reduced the amount of infectious virus in the lungs by more than 99.9%, abolished shedding of virus in pharyngeal secretions and largely prevented H5N1-induced lung pathology.
    [Show full text]
  • Antibody Therapies for the Prevention and Treatment of Viral Infections
    www.nature.com/npjvaccines REVIEW ARTICLE OPEN Antibody therapies for the prevention and treatment of viral infections Georgina Salazar1, Ningyan Zhang1, Tong-Ming Fu 2 and Zhiqiang An1 Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand host–viral interaction and viral pathogenesis mechanisms and to find potential cures for viral infection and disease. With more than 60 recombinant monoclonal antibodies developed for human use in the last 20 years, monoclonal antibodies are now considered a viable therapeutic modality for infectious disease targets, including newly emerging viral pathogens such as Ebola representing heightened public health concerns, as well as pathogens that have long been known, such as human cytomegalovirus. Here, we summarize some recent advances in identification and characterization of monoclonal antibodies suitable as drug candidates for clinical evaluation, and review some promising candidates in the development pipeline. npj Vaccines (2017) 2:19 ; doi:10.1038/s41541-017-0019-3 INTRODUCTION and light chains from B cells of immunized or infected humans or The earliest application of antibodies as a treatment for viral animals are cloned as Fab or scFv fragments and displayed, for infections can be traced back to the early 20th century, use of sera instance on filamentous phage. Virus-specific
    [Show full text]
  • Influenza Vaccines
    Review Antibody Focusing to Conserved Sites of Vulnerability: The Immunological Pathways for ‘Universal’ Influenza Vaccines Maya Sangesland and Daniel Lingwood * The Ragon Institute of MGH, MIT, and Harvard, 400 Technology Square, Cambridge, MA 02139, USA; [email protected] * Correspondence: [email protected] Abstract: Influenza virus remains a serious public health burden due to ongoing viral evolution. Vaccination remains the best measure of prophylaxis, yet current seasonal vaccines elicit strain- specific neutralizing responses that favor the hypervariable epitopes on the virus. This necessitates yearly reformulations of seasonal vaccines, which can be limited in efficacy and also shortchange pandemic preparedness. Universal vaccine development aims to overcome these deficits by redi- recting antibody responses to functionally conserved sites of viral vulnerability to enable broad coverage. However, this is challenging as such antibodies are largely immunologically silent, both following vaccination and infection. Defining and then overcoming the immunological basis for such subdominant or ‘immuno-recessive’ antibody targeting has thus become an important aspect of universal vaccine development. This, coupled with structure-guided immunogen design, has led to proof-of-concept that it is possible to rationally refocus humoral immunity upon normally ‘unseen’ broadly neutralizing antibody targets on influenza virus. Keywords: influenza virus; antibody response; universal vaccine; immunodominance; broadly neutralizing antibodies;
    [Show full text]
  • Antivirals for Respiratory Viral Infections: Problems and Prospects
    640 Antivirals for Respiratory Viral Infections: Problems and Prospects à à à Qiang Liu, MD1, Yuan-hong Zhou, PhD1, Feng Ye1, Zhan-qiu Yang, MD2 1 The First College of Clinical Medical Science, China Three Gorges Address for correspondence Zhan-Qiu Yang, MD, Institute of Medical University/Yichang Central People’s Hospital, Yichang, China Virology, School of Basic Medical Sciences, Wuhan University, 185 2 State Key Laboratory of Virology, Institute of Medical Virology, Donghu Road, Wuhan 430071, China (e-mail: [email protected]). School of Medicine, Wuhan University, Wuhan, China Semin Respir Crit Care Med 2016;37:640–646. Abstract In the past two decades, several newly emerging and reemerging viral respiratory pathogens including several influenza viruses (avian influenza and pandemic influenza), severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory Keywords syndrome coronavirus (MERS-CoV), have continued to challenge medical and public ► respiratory virus health systems. Thereafter, the development of cost-effective, broad-spectrum antiviral ► antiviral agents is the urgent mission of both virologists and pharmacologists. Current antiviral ► entry developments have focused targets on viral entry, replication, release, and intercellular ► replication pathways essential for viral life cycle. Here, we review the current literature on ► pathway challenges and prospects in the development of these antivirals. Respiratory infections are a major cause of morbidity and tion by immune system and inefficacy to protect the host mortality for humans, and most of these infections are caused from a novel antigenic variant.11 Thus, antivirals with novel by respiratory viruses.1 Between 1997 and 2015, several pharmacological activities are highly needed.
    [Show full text]
  • Understanding Drug Resistance and Antibody Neutralization Escape in Antivirals: a Dissertation
    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2016-04-06 Understanding Drug Resistance and Antibody Neutralization Escape in Antivirals: A Dissertation Kristina L. Prachanronarong University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Biochemistry Commons, Biophysics Commons, Cellular and Molecular Physiology Commons, Immunoprophylaxis and Therapy Commons, Pharmacology Commons, Structural Biology Commons, Virology Commons, and the Virus Diseases Commons Repository Citation Prachanronarong KL. (2016). Understanding Drug Resistance and Antibody Neutralization Escape in Antivirals: A Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/M2C01X. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/840 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. UNDERSTANDING DRUG RESISTANCE AND ANTIBODY NEUTRALIZATION ESCAPE IN ANTIVIRALS A Dissertation Presented By KRISTINA PRACHANRONARONG Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences, Worcester in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY APRIL 6, 2016 MD/PHD PROGRAM ii UNDERSTANDING ANTIVIRAL
    [Show full text]